BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30172068)

  • 1. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy.
    Duo Y; Yang M; Du Z; Feng C; Xing C; Wu Y; Xie Z; Zhang F; Huang L; Zeng X; Chen H
    Acta Biomater; 2018 Oct; 79():317-330. PubMed ID: 30172068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PICT-1 triggers a pro-death autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway.
    Chen H; Duo Y; Hu B; Wang Z; Zhang F; Tsai H; Zhang J; Zhou L; Wang L; Wang X; Huang L
    Oncotarget; 2016 Nov; 7(48):78747-78763. PubMed ID: 27729611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer.
    Li Y; Duo Y; Bao S; He L; Ling K; Luo J; Zhang Y; Huang H; Zhang H; Yu X
    Int J Nanomedicine; 2017; 12():6239-6257. PubMed ID: 28894364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
    Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
    Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
    Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
    Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rRNA synthesis inhibitor CX-5461 may induce autophagy that inhibits anticancer drug-induced cell damage to leukemia cells.
    Okamoto S; Miyano K; Kajikawa M; Yamauchi A; Kuribayashi F
    Biosci Biotechnol Biochem; 2020 Nov; 84(11):2319-2326. PubMed ID: 32799625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary autophagy inhibition and glucose metabolism with rattle-structured polydopamine@mesoporous silica nanoparticles for augmented low-temperature photothermal therapy and
    Shao L; Li Y; Huang F; Wang X; Lu J; Jia F; Pan Z; Cui X; Ge G; Deng X; Wu Y
    Theranostics; 2020; 10(16):7273-7286. PubMed ID: 32641992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
    Wei Y; Gao L; Wang L; Shi L; Wei E; Zhou B; Zhou L; Ge B
    Drug Deliv; 2017 Nov; 24(1):681-691. PubMed ID: 28414557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy.
    Chang D; Gao Y; Wang L; Liu G; Chen Y; Wang T; Tao W; Mei L; Huang L; Zeng X
    J Colloid Interface Sci; 2016 Feb; 463():279-87. PubMed ID: 26550786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
    Drygin D; Siddiqui-Jain A; O'Brien S; Schwaebe M; Lin A; Bliesath J; Ho CB; Proffitt C; Trent K; Whitten JP; Lim JK; Von Hoff D; Anderes K; Rice WG
    Cancer Res; 2009 Oct; 69(19):7653-61. PubMed ID: 19738048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.
    Li Y; Duo Y; Bi J; Zeng X; Mei L; Bao S; He L; Shan A; Zhang Y; Yu X
    Int J Nanomedicine; 2018; 13():1241-1256. PubMed ID: 29535520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 induces a survival transcriptional response after nucleolar stress.
    Liao H; Gaur A; Mauvais C; Denicourt C
    Mol Biol Cell; 2021 Oct; 32(20):ar3. PubMed ID: 34319761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting delivery of miR-328 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.
    Li Y; Duo Y; Zhai P; He L; Zhong K; Zhang Y; Huang K; Luo J; Zhang H; Yu X
    Nanomedicine (Lond); 2018 Jul; 13(14):1753-1772. PubMed ID: 30084727
    [No Abstract]   [Full Text] [Related]  

  • 15. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
    Xu H; Di Antonio M; McKinney S; Mathew V; Ho B; O'Neil NJ; Santos ND; Silvester J; Wei V; Garcia J; Kabeer F; Lai D; Soriano P; BanĂ¡th J; Chiu DS; Yap D; Le DD; Ye FB; Zhang A; Thu K; Soong J; Lin SC; Tsai AH; Osako T; Algara T; Saunders DN; Wong J; Xian J; Bally MB; Brenton JD; Brown GW; Shah SP; Cescon D; Mak TW; Caldas C; Stirling PC; Hieter P; Balasubramanian S; Aparicio S
    Nat Commun; 2017 Feb; 8():14432. PubMed ID: 28211448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted and controlled drug delivery by multifunctional mesoporous silica nanoparticles with internal fluorescent conjugates and external polydopamine and graphene oxide layers.
    Tran AV; Shim K; Vo Thi TT; Kook JK; An SSA; Lee SW
    Acta Biomater; 2018 Jul; 74():397-413. PubMed ID: 29775731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
    Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
    Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape.
    Tu J; Wang T; Shi W; Wu G; Tian X; Wang Y; Ge D; Ren L
    Biomaterials; 2012 Nov; 33(31):7903-14. PubMed ID: 22840227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-Sensitive Delivery Vehicle Based on Folic Acid-Conjugated Polydopamine-Modified Mesoporous Silica Nanoparticles for Targeted Cancer Therapy.
    Cheng W; Nie J; Xu L; Liang C; Peng Y; Liu G; Wang T; Mei L; Huang L; Zeng X
    ACS Appl Mater Interfaces; 2017 Jun; 9(22):18462-18473. PubMed ID: 28497681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.